AlzeCure Pharma AB (FRA:AC6) Research & Development : €2.20 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is AlzeCure Pharma AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. AlzeCure Pharma AB's Research & Development for the three months ended in Dec. 2024 was €0.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €2.20 Mil.

AlzeCure Pharma AB Research & Development Historical Data

The historical data trend for AlzeCure Pharma AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB Research & Development Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

6.13

6.50

4.20

2.48

2.17

AlzeCure Pharma AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Research & Development	Get a 7-Day Free Trial															0.63	0.62	0.52	0.48	0.58

AlzeCure Pharma AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.20 Mil.

AlzeCure Pharma AB (FRA:AC6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AlzeCure Pharma AB Research & Development Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (FRA:AC6) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

ALZCUR:Sweden

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatments of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines